Ventyx Biosciences, Inc.
VTYXDelisted Mar 4, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851194
Ventyx Biosciences, Inc. was delisted on Mar 4, 2026; its insiders filed their last Form 4 on Mar 4, 2026; 139 institutions reported holding it in 13F filings for Q4 2025, worth $471.6M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 139
- Q4 2025, +29 vs. previous quarter
- 13F value
- $471.6M
- Reported value at the end of Q4 2025
- Superinvestors holding
- 0
- At the end of Q4 2025
Superinvestors holding VTYX, Q4 2025
No superinvestor reported holding VTYX at the end of Q4 2025.
Latest insider trades
Open-market purchases and sales by Ventyx Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Mohan RajuCEO AND PRESIDENT | SSale | −47.3K | $7.72 | −$365.5K | −2.0%2.37M after | |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Nuss JohnCHIEF SCIENTIFIC OFFICER | SSale | −12.7K | $7.72 | −$97.9K | −2.5%489.5K after | |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Nuss JohnCHIEF SCIENTIFIC OFFICER | SSale | −1.89K | $1.07 | −$2.02K | −0.4%467.2K after | |
| Dec 30, 2024 (view filing) | Dec 27 | 3 days | Nuss JohnCHIEF SCIENTIFIC OFFICER | SSale | −21.1K | $2.36 | −$49.8K | −4.3%464.6K after | |
| Dec 26, 2024 (view filing) | Dec 23 | 3 days | Gujrathi SheilaDirector | PPurchase | +130.0K | $2.31 | +$300.3K | New position130.0K after | |
| Dec 19, 2024 (view filing) | Dec 19 | Same day | Nuss JohnCHIEF SCIENTIFIC OFFICER | SSale | −13.2K | $2.26 | −$29.7K | −2.6%485.7K after | |
| Nov 25, 2024 (view filing) | Nov 22-25 | 3 days | Mohan RajuCEO AND PRESIDENT | PPurchase | +500.0K | $1.92 | +$962.1K | +29.9%2.18M after | 2 lots |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Krueger Christopher WCHIEF BUSINESS OFFICER | SSale | −1.65K | $5.40 | −$8.92K | −0.6%285.0K after | |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Nuss JohnCHIEF SCIENTIFIC OFFICER | SSale | −1.65K | $5.40 | −$8.92K | −0.6%265.0K after | |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Mohan RajuCEO AND PRESIDENT | SSale | −4.31K | $5.40 | −$23.3K | −0.3%1.58M after |
Top 10 13F holders, Q4 2025
The largest institutional positions in Ventyx Biosciences, Inc. at the end of Q4 2025; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 6,484,558 | $58.6M | 4.21% | +2,560,143+65.2% | Added |
| Morgan Stanley | 4,292,951 | $38.8M | 0.00% | +4,049,194+1,661.2% | Added |
| Vanguard Group Inc | 3,943,566 | $35.6M | 0.00% | +173,569+4.6% | Added |
| BlackRock, Inc. | 3,142,440 | $28.4M | 0.00% | +1,959,200+165.6% | Added |
| Tang Capital Management LLC | 2,814,000 | $25.4M | 1.26% | −286,000−9.2% | Reduced |
| Baker Bros. Advisors LP | 2,349,280 | $21.2M | 0.12% | +1,326,150+129.6% | Added |
| Braidwell LP | 1,920,255 | $17.3M | 0.55% | +1,920,255 | New |
| D. E. Shaw & Co., Inc. | 1,665,474 | $15.0M | 0.01% | +1,142,786+218.6% | Added |
| MPM Oncology Impact Management LP | 1,639,061 | $14.8M | 1.69% | +1,639,061 | New |
| Citadel Advisors LLC | 1,563,611 | $14.1M | 0.01% | −316,378−16.8% | Reduced |